编号：2022-022 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------|-------------------|-----------------------| | 投资者关系活 \n动类别 | □现场参观 \n□√其他（电话、线上会议） | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | | | | | | 人保养老 | 中信建投基金 | 中信期货 | 民生信托 中再资产 | | | | 华夏基金 | | 长城基金 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥344,696,330.89, representing an increase of 18.36% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥47,439,961.79, up 12.69% year-on-year, while the net profit excluding non-recurring gains and losses was ¥46,140,566.11, an increase of 16.56%[5]. - The net profit for the third quarter of 2022 was CNY 104,887,601.16, an increase of 18% compared to CNY 88,933,462.49 in the same period last year[20]. - Operating income for the third quarter reached CNY 116,780,742.51, up from CNY 101,463,975.16, reflecting a growth of approximately 15.5% year-over-year[19]. - The total revenue from sales of goods and services was CNY 823,211,488.02, up from CNY 730,647,546.59, indicating a growth of approximately 12.6%[22]. Earnings Per Share - The basic earnings per share (EPS) for the period was ¥0.2863, reflecting an 8.53% increase year-on-year, while diluted EPS was ¥0.2672, up 7.14%[5]. - The basic earnings per share increased to CNY 0.6332 from CNY 0.5519, representing a growth of about 14.7%[20]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,644,701,803.91, a 7.89% increase from the end of the previous year[5]. - As of September 30, 2022, total assets were CNY 1,644,701,803.91, up from CNY 1,524,426,501.68 at the beginning of the year, indicating a growth of 7.9%[17]. - The total liabilities as of September 30, 2022, were CNY 634,030,033.19, slightly up from CNY 633,983,091.90 at the beginning of the year[17]. - The company's equity attributable to shareholders reached CNY 1,010,671,770.72, an increase from CNY 890,443,409.78, reflecting a growth of 13.5%[17]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥62,907,793.14, showing a decrease of 35.60% compared to the previous year[10]. - The cash flow from operating activities generated a net amount of CNY 62,907,793.14, down from CNY 97,683,353.15, a decrease of about 35.5%[23]. - The company reported a cash and cash equivalents balance of CNY 89,909,959.56 at the end of the period, compared to CNY 98,284,359.97 at the end of the previous year, reflecting a decrease of approximately 4.5%[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,434[12]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 34.56% of the shares, with 33,821,441 shares pledged[12]. Borrowings and Investments - The company reported a significant increase in long-term borrowings, which rose by 399.37% to ¥25,000,000.00, attributed to new borrowings during the period[10]. - The short-term borrowings decreased to CNY 257,000,000.00 from CNY 268,342,558.34, a reduction of 4.9%[17]. - The company experienced a net cash outflow from investing activities of CNY 24,225,800.33, an improvement from a net outflow of CNY 198,550,274.06 in the previous year[23]. - The financing activities resulted in a net cash outflow of CNY 21,250,130.68, compared to a net outflow of CNY 130,936,122.11 in the same period last year[23]. Operating Costs and Expenses - The total operating revenue for the third quarter of 2022 reached CNY 869,234,233.67, an increase of 16.6% compared to CNY 745,264,628.80 in the same period last year[18]. - The total operating costs for the same period amounted to CNY 749,807,302.84, reflecting a rise of 16.3% from CNY 644,773,028.12 year-on-year[18]. - The total operating expenses rose to CNY 428,144,471.00, compared to CNY 366,976,813.99, an increase of approximately 16.6%[19]. - Research and development expenses increased to CNY 12,571,577.53, compared to CNY 11,714,744.33, marking a rise of about 7.3%[19]. Government Subsidies - The company received government subsidies amounting to ¥1,724,872.07 during the reporting period, contributing to its financial performance[7].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥524,537,902.78, representing a 15.53% increase compared to ¥454,031,233.06 in the same period last year[23]. - The net profit attributable to shareholders was ¥57,447,639.37, up 22.65% from ¥46,837,320.12 in the previous year[23]. - Basic earnings per share increased by 18.48% to ¥0.3469, compared to ¥0.2928 in the previous year[23]. - The company reported a net profit excluding non-recurring gains and losses of ¥55,472,739.77, a 19.06% increase from ¥46,590,801.43 in the same period last year[23]. - The company achieved a revenue of ¥524,537,902.78, representing a year-on-year increase of 15.53% compared to ¥454,031,233.06 in the previous year[53]. - The company's main business revenue reached ¥524.1 million, representing a year-on-year increase of 15.55%[55]. - The net profit for the first half of 2022 was CNY 67,436,924.64, representing a 22.1% increase from CNY 55,092,402.91 in the previous year[168]. - The total comprehensive income for the first half of 2022 was CNY 68,806,549.84, compared to CNY 59,299,116.77 in the first half of 2021, indicating a growth of 16.4%[173]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,621,253,562.39, a 6.35% increase from ¥1,524,426,501.68 at the end of the previous year[23]. - The company's total assets reached CNY 1,614,133,879.25, compared to CNY 1,529,630,827.36 at the beginning of the year, reflecting a growth of 5.5%[164]. - The total liabilities increased to CNY 653,020,092.21, up from CNY 644,189,946.00, indicating a rise of 1.3%[165]. - The company's asset-liability ratio stands at 41.11%, a slight decrease of 0.48% from the previous year[156]. Cash Flow - The net cash flow from operating activities decreased by 26.40% to ¥43,965,639.45, down from ¥59,736,164.46 in the same period last year[23]. - The company's cash and cash equivalents increased by 489.41%, reaching ¥55,165,108.36, mainly due to reduced bank loan repayments and increased bank borrowings[53]. - The ending balance of cash and cash equivalents was ¥85,559,440.63, compared to ¥234,174,509.64 at the end of the first half of 2021, reflecting a decrease of 63.4%[178]. - The total cash outflow for operating activities was ¥504,632,815.44, which increased by 29.0% from ¥391,065,369.54 in the previous year[177]. Research and Development - The company has completed clinical phase III trials for three new traditional Chinese medicine products, including Longcen Pelvic Comfort Granules[36]. - The company has a strategic focus on expanding its market presence and enhancing its product portfolio through continuous research and development[36]. - The company's R&D investment increased to ¥13,972,036.81, up 17.51% from ¥11,889,702.71 in the previous year, reflecting a growing commitment to innovation[53]. - Research and development expenses for the first half of 2022 were CNY 12,384,704.15, a decrease of 14.7% compared to CNY 14,520,861.28 in the same period of 2021[172]. Market and Product Development - The company has a focus on gynecological and urological medications, with products like Ningpitai Capsule and Kucan Gel being unique in the domestic market[33][34]. - The leading product, Kuntai Capsule, is a national essential drug and has ranked 2nd in the gynecology medication field in the 2020 and 2021 Clinical Value Chinese Medicine Brand List[32]. - The company has established a stable supply chain for raw materials, leveraging the rich medicinal resources available in Guizhou province, which accounts for 89.81% of the 363 key varieties surveyed nationwide[51]. - The company is focused on expanding its market reach, with its products covering over 11,500 hospitals and 85,000 retail outlets nationwide[50]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities, ensuring compliance with environmental regulations[95]. - The company emphasizes social responsibility by protecting investor rights, enhancing employee welfare, and engaging in community service[104]. - The company has introduced advanced energy-saving and environmental protection equipment to improve fuel utilization and reduce carbon emissions[103]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. Shareholder and Equity Information - The total number of shares before the change was 164,048,027, with a total after the change of 165,721,702, reflecting an increase of 1,673,675 shares[132]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 36.55% of the shares, totaling 60,576,547 shares, with 33,821,441 shares pledged[135]. - The company has not disclosed any significant impacts on financial metrics such as basic and diluted earnings per share due to the share changes[134]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[139].

Group 1: Event Details - The event is the "2021 Annual Performance Presentation and Investor Reception Day" scheduled for May 13, 2022, from 09:30 to 11:30 [1] - The event is organized by the Guizhou Securities Regulatory Bureau, Guizhou Securities Association, and Shenzhen Panorama Network Co., Ltd. [1] - The event will be held on the "Panorama Roadshow" platform [1] Group 2: Company Participation - Representatives from the company include Chairman and General Manager Dong Dalun, Director and Deputy General Manager Wang Jinhua, Secretary of the Board and Deputy General Manager Wang Guangping, and Chief Financial Officer Zeng Zhihui [1] - The company aims to enhance communication with investors and improve investor relations management [1] Group 3: Investor Engagement - The company is collecting questions from investors in advance to address common concerns during the event [1] - Investors can submit their questions via a dedicated webpage [1] - The company encourages active participation from investors [1]

Financial Performance - The company's operating revenue for Q1 2022 was ¥249,216,213.05, representing a 16.10% increase compared to ¥214,656,599.98 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was ¥30,879,340.57, up 21.73% from ¥25,366,384.98 year-on-year[3] - Basic earnings per share increased by 18.08% to ¥0.1868, compared to ¥0.1582 in the same period last year[3] - The operating profit for the first quarter was CNY 34,639,863.10, up from CNY 30,472,241.92, reflecting a growth of 7.1% year-over-year[18] - The total comprehensive income for the first quarter was CNY 30,879,340.57, compared to CNY 25,366,384.98, marking an increase of 21.5%[18] Cash Flow - The net cash flow from operating activities decreased by 77.96% to ¥3,695,741.81, down from ¥16,766,677.68 in the previous year[6] - The cash flow from investment activities for Q1 2022 was ¥31,179,154.70, a significant recovery from -¥65,463,297.81 in the previous year[6] - The cash and cash equivalents at the end of the period amounted to CNY 144,358,114.14, compared to CNY 226,589,843.63 at the end of the previous year, a decrease of 36.3%[21] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,588,465,962.04, a 4.20% increase from ¥1,524,426,501.68 at the end of the previous year[3] - The total liabilities increased slightly to RMB 644,546,790.79 from RMB 633,983,091.90 at the beginning of the year[14] - The company's total equity attributable to shareholders increased by 6.01% to ¥943,919,171.25 from ¥890,443,409.78 at the end of the previous year[3] Research and Development - Research and development expenses surged by 178.79% to ¥3,589,480.60, compared to ¥1,287,534.50 in the previous year[6] - Research and development expenses increased significantly to RMB 3,589,480.60, compared to RMB 1,287,534.50 in the same quarter of the previous year, reflecting a growth of 179.3%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,944[8] - The company raised CNY 83,000,000.00 through borrowings, significantly higher than CNY 13,000,000.00 in the previous year, indicating a strategic move to enhance liquidity[21] Operating Costs - The total operating costs for the first quarter of 2022 were RMB 214,995,242.32, up 17.0% from RMB 183,991,577.13 in the previous year[16] - Accounts receivable stood at RMB 218,276,635.91, showing a slight decrease from RMB 222,775,435.76 at the beginning of the year[12] - Inventory levels increased to RMB 154,519,844.54 from RMB 118,770,773.96, indicating a growth of 30.2%[13] - The short-term borrowings rose to RMB 308,000,000.00 from RMB 268,342,558.34, reflecting a growth of 14.8%[13] Government Subsidies and Tax - The company received government subsidies amounting to ¥1,364,741.35, an increase of 78.13% from ¥766,142.44 in the previous year[6] - The company incurred a total tax expense of CNY 3,754,291.98, down from CNY 4,916,577.28, a reduction of 23.6% year-over-year[18]

Financial Performance - The company's operating revenue for 2021 was ¥969,844,472.18, representing a 29.15% increase compared to ¥750,946,390.31 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥100,605,308.02, a 35.76% increase from ¥74,103,210.31 in 2020[20]. - The net profit after deducting non-recurring gains and losses was ¥93,839,366.09, up 32.21% from ¥70,977,065.18 in 2020[20]. - The basic earnings per share for 2021 was ¥0.6193, a 34.48% increase from ¥0.4605 in 2020[20]. - The total operating revenue for 2021 was ¥969,844,472.18, representing a year-on-year increase of 29.15% compared to ¥750,946,390.31 in 2020[59]. - The main business revenue accounted for ¥968,695,455.00, which is 99.88% of total revenue, with a year-on-year growth of 29.13%[62]. - The gynecological product category generated ¥686,491,923.90, making up 70.78% of total revenue, with a growth rate of 31.83%[59]. - The gross profit margin for the main business was 79.28%, slightly up by 1.27% from the previous year[62]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[132]. - The company plans to set a revenue guidance of 1.5 billion RMB for the next fiscal year, projecting a growth rate of 25%[132]. Cash Flow and Investments - The net cash flow from operating activities decreased by 29.28% to ¥124,300,304.12 from ¥175,767,527.16 in 2020[20]. - The total cash inflow from operating activities increased by 19.92% to ¥1,002,079,539.69 in 2021 compared to ¥835,614,919.37 in 2020[73]. - Investment cash inflow surged by 93.15% to ¥553,082,000.00 in 2021, up from ¥286,351,416.78 in 2020[74]. - Financing cash inflow dropped by 47.07% to ¥300,811,607.40 in 2021, compared to ¥568,300,000.00 in 2020[74]. - The total amount of capitalized R&D investment decreased by 43.76% to ¥8,512,930.57 in 2021 from ¥15,135,456.00 in 2020[71]. - The company has allocated RMB 8,000 million to purchase wealth management products and RMB 3,000 million to temporarily supplement working capital[88]. - The company reported a usage rate of 34.83% for the raised funds, indicating that a significant portion remains unutilized[87]. - The company has committed to using the remaining funds from terminated projects for new initiatives, specifically the traditional Chinese medicine formula granule project[92]. Research and Development - The company has established three major R&D bases in Shanghai and Guiyang, forming a systematic R&D structure[45]. - The company has developed three new traditional Chinese medicine products that have completed Phase III clinical trials, with a total of 445 provincial standard varieties of traditional Chinese medicine formula granules and 60 national standard filings[52]. - Research and development expenses increased by 53.26% to ¥20,376,605.27, reflecting a focus on enhancing product offerings[69]. - The company emphasizes a "production generation, reserve generation, development generation" approach in its R&D strategy for traditional Chinese medicine[43]. - The company is committed to enhancing its research and development efforts to drive innovation in its product offerings[122]. Market and Product Development - The company has achieved a market scale of over 100 million for multiple key products, including Kuntai Capsule and Kushi Gel[35]. - The company plans to enhance market promotion for its exclusive products, aiming to expand market share and attract innovative talent[36]. - The company aims to strengthen the promotion of existing major products and enhance sales team construction, with a focus on expanding the OTC market and increasing online sales investment[102]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[132]. - The company plans to produce new products such as Re-Lin-Qing Syrup and Xie-Yu-Jiang-Zhi Capsule in the future[46]. Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations[111]. - The board of directors consists of three independent directors, meeting the requirement of one-third of the total board members[112]. - The company has a dedicated internal audit department to oversee daily operations and major related transactions[114]. - The company has established a clear organizational structure to prevent fraud risks through separation of incompatible duties[162]. - The company has made provisions for bad debts based on prudence principles at the end of the reporting period[105]. Environmental Responsibility - The company has maintained compliance with environmental regulations, but future changes in laws may increase environmental costs[106]. - The company has implemented advanced environmental management technologies to reduce carbon emissions, improving fuel utilization efficiency and reducing CO2 emissions[179]. - The company has established a management system for energy efficiency and carbon emission reduction[179]. - The company has a solid waste management system in place, including the collection and recycling of waste packaging materials and the disposal of hazardous waste by qualified units[176]. - The company conducts annual emergency response training and drills as part of its environmental incident emergency plan[177]. Employee and Stakeholder Relations - The company has a total of 261 production personnel, 382 sales personnel, and 175 technical personnel[151]. - The company has established a salary system based on employee contributions, with performance-based compensation for market personnel[152]. - Employee rights are protected through a competitive compensation system and a focus on employee health and corporate culture[181]. - The company has implemented a stock incentive plan for its executives, which is expected to align their interests with those of shareholders[122]. - The management team emphasizes a commitment to sustainability, with plans to implement eco-friendly practices in production by 2023[132]. Risk Management - The company acknowledges the risks associated with drug development, including long cycles and high costs, and is committed to improving R&D efficiency and protecting intellectual property[104]. - The company has implemented measures to control accounts receivable risk, including enhancing the assessment of the business operation center and monitoring the entire sales process[105]. - The company has established a risk response strategy based on its strategic goals and development needs[162]. - The company has actively engaged with stakeholders to balance interests and promote sustainable development[115]. - The company has made improvements to its internal control system to adapt to changing external environments and internal management requirements[162].

Financial Performance - The company's revenue for Q3 2021 reached ¥291,233,395.74, representing a year-on-year increase of 21.86%[3] - Net profit attributable to shareholders was ¥42,096,142.37, up 17.42% compared to the same period last year[3] - The basic earnings per share (EPS) increased to ¥0.3693, reflecting an 18.37% growth year-on-year[3] - Operating income for the year-to-date period was ¥745,264,628.80, a significant increase of 37.54% driven by higher sales of gynecological products[8] - The net profit for the third quarter of 2021 was CNY 88,933,462.49, representing an increase of 45.9% compared to CNY 61,056,054.17 in the same period last year[19] - The total comprehensive income attributable to the parent company was CNY 88,933,462.49, up from CNY 61,056,054.17, marking a 45.9% increase[20] - The company reported a total operating profit of CNY 101,463,975.16, which is an increase from CNY 70,558,767.01 in the same quarter last year[19] - The total revenue from sales of goods and services received was CNY 730,647,546.59, compared to CNY 562,219,123.37 in the previous year, reflecting a growth of 30%[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,553,224,196.03, a 1.13% increase from the end of the previous year[4] - The total assets of the company as of September 30, 2021, were RMB 1,553,224,196.03, slightly up from RMB 1,535,933,766.56 at the end of 2020[17] - The total liabilities decreased to RMB 660,544,340.81 from RMB 707,636,495.11, indicating a reduction of 6.7%[16] - Total liabilities reached approximately ¥715.28 million, with current liabilities at ¥513.64 million and non-current liabilities at ¥201.64 million[27] - The company's equity attributable to shareholders rose to ¥892,679,855.22, marking a 7.77% increase from the previous year[4] - The company's equity totaled approximately ¥828.30 million, with retained earnings of ¥341.07 million[27] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥97,683,353.15, showing a slight decrease of 2.69%[3] - Cash flow from operating activities generated a net amount of CNY 97,683,353.15, slightly down from CNY 100,384,660.05 in the previous year[21] - Total cash inflow from investment activities was CNY 425,180,124.83, compared to CNY 203,885,507.08 in the prior year, indicating a significant increase of 108.5%[22] - The net cash flow from investment activities was negative at CNY -198,550,274.06, an improvement from CNY -300,483,444.24 in the same period last year[22] - Cash flow from financing activities resulted in a net outflow of CNY -130,936,122.11, compared to a net inflow of CNY 245,757,737.78 in the previous year[22] Research and Development - Research and development expenses surged by 111.62% to ¥11,714,744.33, indicating increased investment in innovation[9] - Research and development expenses increased to RMB 11,714,744.33, up from RMB 5,535,848.58, marking a growth of 111.5% year-on-year[17] Inventory and Receivables - The company reported a 42.80% increase in accounts receivable, totaling ¥255,336,062.94, primarily due to sales growth[8] - Accounts receivable increased significantly to RMB 255,336,062.94, compared to RMB 178,806,442.88 at the end of 2020, reflecting a growth of 42.8%[14] - The inventory level rose to RMB 91,524,859.77 from RMB 86,821,180.60, reflecting an increase of 5.5%[15] Other Financial Information - The company's cash and cash equivalents decreased to RMB 98,284,359.97 from RMB 330,087,402.99 at the end of 2020, representing a decline of 70.2%[14] - The weighted average return on equity was 4.91%, reflecting a 0.26% increase compared to the previous year[4] - The company's net profit for the period was impacted by credit impairment losses of RMB -3,635,322.39, compared to RMB -1,541,064.86 in the previous year[17] - The company plans to continue expanding its market presence and investing in new technologies to enhance its product offerings and operational efficiency[23] - The company has not undergone an audit for the third quarter report[28] - The report indicates a significant increase in total liabilities compared to the previous period, reflecting a rise of approximately ¥7.64 million[27] - The company is implementing new leasing standards, which may affect future financial reporting[28]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 454,031,233.06, representing a 49.91% increase compared to CNY 302,862,307.16 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 46,837,320.12, an increase of 85.83% from CNY 25,204,359.22 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,590,801.43, up 90.36% from CNY 24,475,388.50 in the previous year[20]. - The basic earnings per share increased to CNY 0.4100, an 86.96% rise from CNY 0.2193 in the same period last year[20]. - The diluted earnings per share were CNY 0.3811, reflecting an increase of 84.37% compared to CNY 0.2067 in the previous year[20]. - The weighted average return on equity was 5.57%, up from 3.41% in the same period last year, an increase of 2.16%[20]. - The company reported a significant increase in financial expenses, which rose by 554.25% to ¥8,208,493.53, primarily due to increased loan interest and reduced government subsidies[54]. - The company reported a net profit of 4,659.08 million yuan for the current period, representing a 90.36% increase compared to the same period last year[154]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,534,079,519.74, a slight decrease of 0.12% from CNY 1,535,933,766.56 at the end of the previous year[20]. - The total liabilities decreased to 481,262,685.67 yuan from 513,639,094.28 yuan in the previous year[160]. - The company's total assets at the end of the reporting period amounted to 1,190 million yuan, showing a growth from the previous period's total assets of 1,313.8 million yuan[188]. - The total liabilities at the end of the reporting period were 373.89 million yuan, a decrease from 846.22 million yuan in the previous period, indicating a reduction of approximately 56%[188]. Cash Flow - The net cash flow from operating activities was CNY 59,736,164.46, showing a decrease of 3.00% compared to CNY 61,586,412.45 in the same period last year[20]. - The net cash flow from investment activities improved by 102.66%, reaching ¥5,672,551.43, mainly due to the maturity of financial products[54]. - The net cash flow from operating activities generated a net amount of CNY 59,736,164.46, slightly down from CNY 61,586,412.45 in the first half of 2020[177]. - The total cash and cash equivalents at the end of the period stood at ¥234,174,509.64, down from ¥245,929,798.90 at the end of the previous period, indicating a decrease in liquidity[182]. Research and Development - The company focuses on the research, development, production, and sales of traditional Chinese medicine, with a product line that includes eight dosage forms and two production lines for traditional Chinese medicine pieces[28]. - Research and development investment amounted to ¥11,889,702.71, reflecting a 5.25% increase from ¥11,296,412.99, indicating continued commitment to innovation[54]. - The company emphasizes a strategy of "producing one generation, reserving one generation, and developing one generation" for its R&D efforts[36]. - The company has three new traditional Chinese medicine products that have completed Phase III clinical trials and 445 varieties of traditional Chinese medicine formula granules in clinical research[36]. Market and Sales - The company aims to leverage its brand advantage to enhance market promotion of its exclusive products and attract top talent for technological innovation[46]. - The marketing strategy emphasizes professional academic promotion, enhancing product visibility and trust among healthcare professionals through various academic forums and clinical trials[40]. - Gynecology products generated ¥323,202,853.44, making up 71.19% of total revenue, with a significant increase of 55.66% year-on-year[56]. - The company has established a strong market presence with its leading products, including Kuntai capsules and Ningpitai capsules, achieving over ¥100 million in market scale for several key products[46]. Environmental Compliance - The company has two wastewater treatment plants, with the old plant having a daily processing capacity of 2,000 tons and the new plant 720 tons[84]. - The wastewater treatment process for the old plant includes UASB, biological contact oxidation, and two-stage filtration, ensuring compliance with discharge standards[84]. - The company has obtained pollution discharge permits for both old and new plants, with the old plant's permit valid until June 28, 2023, and the new plant's until May 24, 2025[87]. - The company reported no exceedances in pollutant emissions for COD and ammonia nitrogen at both plants[83]. Shareholder and Equity Information - The company plans to distribute 4 additional shares for every 10 shares held, using capital reserves, with no cash dividends proposed[4]. - The company has allocated 15,021,170.80 yuan for share repurchase during the reporting period, with total cash dividends amounting to 15,021,170.80 yuan, accounting for 100% of the distributable profit[77]. - The total number of ordinary shareholders at the end of the reporting period was 11,954[132]. - The largest shareholder, Guiyang Xintian Biological Technology Development Co., Ltd., holds 38.89% of the shares, with a reduction of 6 million shares during the reporting period[132]. Corporate Governance - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[76]. - The company emphasizes the protection of investor rights and has established a reasonable dividend plan to actively return profits to shareholders[92]. - The company has not reported any significant litigation or arbitration matters during the reporting period[101].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 214,656,599.98, representing a 113.84% increase compared to CNY 100,379,992.91 in the same period last year[8] - Net profit attributable to shareholders reached CNY 25,366,384.98, a significant increase of 714.60% from CNY 3,113,965.50 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 24,867,023.76, up 494.51% from CNY 4,182,758.45 in the previous year[8] - Basic earnings per share rose to CNY 0.2215, marking a 717.34% increase from CNY 0.0271 in the same quarter last year[8] - The company reported a significant increase in other equity instruments from CNY 183,644,362.39 to CNY 233,644,362.39, a rise of approximately 27%[30] - The total comprehensive income for the period was CNY 15,044,870.29, reflecting the same figure as the net profit[44] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,525,743,416.24, a slight decrease of 0.66% from CNY 1,535,933,766.56 at the end of the previous year[8] - Total liabilities decreased from CNY 707,636,495.11 to CNY 687,024,626.73, a decrease of approximately 2.9%[31] - Non-current assets increased from CNY 723,053,744.10 to CNY 794,202,565.56, an increase of about 9.8%[30] - Total liabilities decreased to CNY 673,758,824.02 from CNY 701,494,768.15, while total equity increased slightly to CNY 819,848,473.14 from CNY 819,748,469.77[38] - The total assets increased from 1,535,933,766.56 CNY to 1,547,596,915.49 CNY, reflecting an adjustment of 11,663,148.93 CNY[54] Cash Flow - The net cash flow from operating activities was CNY 16,766,677.68, down 52.65% from CNY 35,411,350.35 in the same period last year[8] - The company's net cash flow from investment activities improved by 72.76% to -CNY 65,463,297.81, mainly due to an increase in the redemption of bank wealth management products[15] - The net cash flow from investment activities was -76,595,269.29 CNY, a decrease from -252,781,090.14 CNY year-over-year[51] - The cash inflow from financing activities was 13,000,000.00 CNY, down from 214,800,000.00 CNY in the previous year[51] - The cash outflow for repaying debts was 48,000,000.00 CNY, compared to 25,000,000.00 CNY in the previous year[51] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,517[11] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 38.90% of the shares, with 45,568,962 shares pledged[11] - The company repurchased a total of 3,170,012 shares, accounting for 2.71% of the total share capital, with a total expenditure of CNY 25,498,647.29[19] Expenses - The company's financial expenses surged by 264.26% to CNY 3,787,069.84, primarily due to a decrease in interest subsidies received[15] - The company's research and development expenses decreased by 33.72% to CNY 1,287,534.50, reflecting a reduction in capitalized R&D expenditures[15] - Total operating costs amounted to ¥183,991,577.13, compared to ¥94,727,324.68 in the previous year, reflecting a rise in sales expenses to ¥105,947,606.46 from ¥49,789,784.22[38] Other Financial Metrics - The company received government subsidies amounting to CNY 766,142.44 during the reporting period[9] - The company incurred a credit impairment loss of CNY -780,480.80 during the quarter[46] - The company adjusted its financial statements to comply with new leasing standards, impacting the balance sheet[52] - The first quarter report was not audited, which may affect the reliability of the financial data presented[59]

Financial Performance - The company's operating revenue for 2020 was CNY 750,946,390.31, a decrease of 2.90% compared to CNY 773,337,464.67 in 2019[16]. - The net profit attributable to shareholders for 2020 was CNY 74,103,210.31, representing an increase of 3.75% from CNY 71,422,165.77 in 2019[16]. - The net profit after deducting non-recurring gains and losses was CNY 70,977,065.18, up by 3.37% from CNY 68,660,960.23 in the previous year[16]. - The net cash flow from operating activities surged to CNY 175,767,527.16, a significant increase of 421.13% compared to CNY 33,728,459.89 in 2019[16]. - The basic earnings per share for 2020 was CNY 0.6447, an increase of 4.27% from CNY 0.6183 in 2019[16]. - The diluted earnings per share decreased by 2.65% to CNY 0.6019 from CNY 0.6183 in the previous year[16]. - The total assets at the end of 2020 were CNY 1,535,933,766.56, reflecting a growth of 41.74% from CNY 1,083,647,584.75 at the end of 2019[16]. - The weighted average return on net assets was 9.76%, down from 10.72% in 2019[16]. - The company reported a total of 32 drug production licenses, including 10 in the national medical insurance catalog and 1 in the national essential drug catalog[26]. Market and Product Development - The company is focused on expanding its market presence in gynecology and urology, leveraging rich traditional Chinese medicine resources[25]. - The leading product, Kuntai Capsule, is a national essential drug and ranked 2nd in the gynecology medication field in the 2018 national Chinese medicine competition[26]. - The company has developed a unique product, Kucan Gel, which is the first vaginal carbomer gel in China, aimed at treating chronic gynecological inflammation[27]. - The company has maintained a steady growth trajectory in the traditional Chinese medicine market, ranking 70th among Chinese traditional medicine companies in 2019[25]. - The company is currently producing 12 main traditional Chinese medicine products, with 4 products in small-scale production and 2 products planned for future production[30]. - The company has completed Phase III clinical trials for three new traditional Chinese medicine products and is advancing related follow-up work as planned[31]. - The company has 421 traditional Chinese medicine formula granules in clinical research, with three new drug products having completed phase III clinical trials[45][46]. Research and Development - The company has 36 invention patents, 1 utility model patent, and 10 design patents, with 11 national new drug certificates and 32 drug approval numbers as of the reporting period[31]. - The company is enhancing its R&D capabilities through the establishment of a new R&D center, which is expected to facilitate the transformation of research results into marketable products[54]. - The total R&D investment was CNY 28,430,751.42, which is 3.79% of operating revenue, a decrease of 0.20% from the previous year[72]. - The number of R&D personnel increased by 9.92% to 144, representing 13.66% of the total workforce[72]. - The capitalized R&D investment increased by 55.68% to CNY 15,135,456.00, accounting for 53.24% of total R&D investment[72]. Cash Flow and Financing - The total cash inflow from financing activities rose by 86.63% to ¥568,300,000.00, driven by increased short-term borrowings and the issuance of convertible bonds[73]. - The net cash flow from financing activities surged by 2,389.32% to ¥299,330,832.63 from ¥12,024,602.25 in the previous year[73]. - The cash and cash equivalents increased by 250.00% to ¥148,430,922.07 from ¥42,409,015.61 in 2019[73]. - The company raised a total of RMB 31,702.02 million from its initial public offering, with a net amount of RMB 28,969.23 million after deducting issuance costs[88]. - The company has committed to invest RMB 7,337 million in a new traditional Chinese medicine extraction production line, with an investment progress of 20.41%[90]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1.2 per 10 shares (including tax) to all shareholders[4]. - The total cash dividend (including other methods) amounted to RMB 16,377,461.28, representing 100% of the distributable profit[112]. - In 2020, cash dividends accounted for 22.10% of the net profit attributable to ordinary shareholders, compared to 39.78% in 2019 and 30.64% in 2018[110]. - The company has a commitment to maintain a minimum cash dividend ratio of 20% during its growth phase[112]. Corporate Governance and Compliance - The company has established strict limitations on financial transactions between the controlling shareholder and the company, prohibiting the use of company funds for personal expenses[114]. - The company has committed to transparency in any financial dealings with its controlling shareholder, ensuring compliance with relevant regulations[114]. - The company has not encountered any issues with the use of raised funds or other situations during the reporting period[93]. - The company has not reported any significant accounting errors that require retrospective restatement during the reporting period[122]. - The company is under the supervision of regulatory bodies and self-regulatory organizations to ensure compliance with commitments made[117]. Social Responsibility and Environmental Compliance - In 2020, the company donated a total of CNY 2 million to support COVID-19 prevention efforts and various poverty alleviation initiatives[152]. - The company has established a scientific and reasonable incentive mechanism to protect employee rights and interests[149]. - The company has implemented a comprehensive pollution prevention strategy, including the use of clean energy for boilers, resulting in emissions below the standards set by GB13271-2014[161]. - The company conducts annual emergency response training and drills as part of its environmental incident management plan[163]. - The company has reported no exceedances in pollutant discharge limits for key pollutants such as COD and ammonia nitrogen[159].